Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy. Resistance to PZA is usually accompanied by loss of pyrazinamidase (PZase) activity in Mycobacterium tuberculosis. PZase converts PZA to bactericidal pyrazinoic acid, and the loss of PZase activity is associated with PZA...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Scorpio, A, Lindholm-Levy, P, Heifets, L, Gilman, R, Siddiqi, S, Cynamon, M, Zhang, Y
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 1997
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC163747/
https://ncbi.nlm.nih.gov/pubmed/9055989
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak